Sec Form 4 Filing - BRATTON DOUGLAS K @ Aquestive Therapeutics, Inc. - 2018-07-24

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person BRATTON DOUGLAS K 2. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [ AQST] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 201 MAIN STREET, SUITE 1900 3. Date of Earliest Transaction (MM/DD/YY) 07/24/2018 (Street) FORT WORTH, TX76102 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/24/2018 P 165,000 A $ 15 165,000 I See Footnotes ( 1 ) ( 2 ) ( 8 ) Common Stock 75,085 D Common Stock 2,249,077 I See Footnotes ( 2 ) ( 3 ) ( 8 ) Common Stock 2,213,314 I See Footnotes ( 2 ) ( 4 ) ( 8 ) Common Stock 4,032,907 I See Footnotes ( 2 ) ( 5 ) ( 8 ) Common Stock 2,755,541 I See Footnotes ( 2 ) ( 6 ) ( 8 ) Common Stock 87,455 I See Footnotes ( 7 ) ( 8 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other BRATTON DOUGLAS K 201 MAIN STREET SUITE 1900 FORT WORTH, TX76102 X X Monoline Partners, L.P. C/O BRATTON CAPITAL MANAGEMENT 201 MAIN STREET, SUITE 1900 FORT WORTH, TX76102 X Bratton Capital Management, L.P. 201 MAIN STREET SUITE 1900 FORT WORTH, TX76102 X Bratton Capital Inc. 201 MAIN STREET SUITE 1900 FORT WORTH, TX76102 X Signatures /s/ Douglas K. Bratton 07/26/2018 Signature of Reporting Person Date /s/ John Cochran, Vice President of Bratton Capital, Inc., general partner of Bratton Capital Management, L.P., general partner of MonoLine Partners, L.P. 07/26/2018 Signature of Reporting Person Date /s/ John Cochran, Vice President of Bratton Capital, Inc., general partner of Bratton Capital Management, L.P. 07/26/2018 Signature of Reporting Person Date /s/ John Cochran, Vice President of Bratton Capital, Inc. 07/26/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )These securities are beneficially owned by MonoLine Partners, L.P. ("MonoLine"). ( 2 )These securities are owned, as indicated, by MonoLine, MRX Partners, LLC ("MRX Partners"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, MRX Partners, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities". Bratton Capital Management, L.P. ("Bratton Capital Management") is the general partner of each of the Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by the Monoline Entities. ( 3 )These securities are beneficially owned by MRX Partners. ( 4 )These securities are beneficially owned by Monoline Rx. ( 5 )These securities are beneficially owned by Monoline II. ( 6 )These securities are beneficially owned by Monoline III. ( 7 )These securities are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. The Reporting Person, Douglas K. Bratton, is the sole director of Bratton and has voting and investment power over all shares held by Monosol. ( 8 )Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol. Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.